Former top FDA official Howard Sklamberg doesn’t see how loosening federal restrictions will lead to a crackdown on state-legal markets.

President Joe Biden’s administration is poised to make the biggest shift in federal drug policy in decades by loosening marijuana restrictions, but the move is sparking blowback from an unlikely constituency: legalization advocates.

They argue that moving marijuana to a lower classification would do nothing to address the federal-state divide in marijuana laws, fail to address the impactsof criminalization, disrupt existing state-regulated cannabis markets, lead multibillion-dollar pharmaceutical companies to dominate the medical cannabis industry and spur a potential federal crackdown.

Howard Sklamberg, an attorney and former top official at the FDA’s Center for Drug Evaluation and Research, argues those fears are alarmist and misguided. He doesn’t believe the cannabis industry needs to worry about a crackdown if the drug is moved from Schedule I to III under the Controlled Substances Act, as recommended by the Food and Drug Administration after a review of the scientific evidence.

“If you’re going to launch an enforcement initiative against cannabis, why would you start off with saying, ‘Oh, by the way, it’s less of a risk than we thought,’” Sklamberg said in an interview with POLITICO. “You would use your power under Schedule I and go after it.” [Read More @ Politico]